

Notice of Distribution Model for Cabometyx®

This notice provides information for 340B covered entities regarding the distribution of Cabometyx® (cabozantinib):

CABOMETYX	60 MG TABLET	42- 88-0023-26	Bottle of 30 tablets
CABOMETYX	20 MG TABLET	42 388-0024-26	Bottle of 30 tablets
CABOMETYX	40 MG TABLET	42 388-0025-26	Bottle of 30 tablets

Cabometyx is an orphan drug approved to treat a small patient population, and Exelixis therefore distributes Cabometyx through an authorized network of specialty pharmacies and specialty distributors that are equipped to successfully facilitate patient care. Any customer may purchase Cabometyx through this network. Those facilities (including 340B entities) that have an on-site pharmacy may acquire Cabometyx through one of our specialty distributor partners. For any facility without an on-site pharmacy, Cabometyx may be acquired through one of Exelixis' in-network specialty pharmacy partners. Exelixis' in-network specialty pharmacy and specialty distributor partners are as follows:

Specialty Pharmacies (U.S.)

- Accredo Specialty Pharmacy
- Advanced Care Scripts (ACS)
- AllianceRx Walgreens Prime
- Avella Specialty Pharmacy
- Biologics, Inc.
- BriovaRx
- Cigna Specialty Pharmacy (Accredo)
- CVS Caremark Specialty Pharmacy
- Diplomat Specialty Pharmacy
- Humana Specialty Pharmacy
- US Bioservices

Specialty Pharmacy (Puerto Rico)

- Axiom Healthcare Puerto Rico

Specialty Distributors for Physician Dispensing Offices (for affiliated GPO members)

- Cardinal Health Specialty Distribution
- McKesson Specialty Health
- Oncology Supply

Specialty Distributors for Institutions/Hospitals

- ASD Healthcare
- Cardinal Health Specialty Distribution
- McKesson Plasma and Biologics

Specialty Distributors (Puerto Rico)

- Cardinal Health Puerto Rico
- Caesar Castillo, Inc.

Exelixis takes its obligations under the 340B program seriously and makes every effort to ensure that Cabometyx is available to eligible 340B covered entities at the applicable statutory ceiling price, in a manner that is no more restrictive than it is for non-340B entities.

The distribution model described above is consistent with section 340B(a)(1) of the Public Health Service Act, which requires manufacturers to “offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.”

If you have any questions regarding access to Cabometyx, please contact Darnell Turner at 650-837-8155.